View in EDS

Four-year survival outcomes with dostarlimab plus chemotherapy in dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.

Saved in:
Bibliographic Details
Title: Four-year survival outcomes with dostarlimab plus chemotherapy in dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
Authors: Powell, Matthew1 (AUTHOR), Zub, Oleksandr2 (AUTHOR), Gilbert, Lucy3 (AUTHOR), Koliadi, Anthoula4 (AUTHOR), Willmott, Lyndsay5 (AUTHOR), Black, Destin6 (AUTHOR), Ronzino, Graziana7 (AUTHOR), Sharma, Sudarshan8 (AUTHOR), Gropp-Meier, Martina9 (AUTHOR), Landrum, Lisa10 (AUTHOR), Thijs, Anna11 (AUTHOR), Lokich, Elizabeth12 (AUTHOR), Gold, Michael13 (AUTHOR), Gill, Sarah14 (AUTHOR), McCourt, Carolyn1 (AUTHOR), Cass, Ilana15 (AUTHOR), Grimshaw, Matthew16 (AUTHOR), Austin, Laura17 (AUTHOR), Edelson, Mitchell18 (AUTHOR), Nøttrup, Trine19 (AUTHOR)
Source: Gynecologic Oncology. May2026:Supplement, Vol. 208, pS65-S66. 2p.
Database: Academic Search Ultimate
Description
ISSN:00908258
DOI:10.1016/j.ygyno.2026.01.779